Because phase 2 trials are designed to find a signal and pick doses, not to prove a durable, safe benefit in the broad population who would eventually use a drug
The manufacturer recommends 10 to 15 ml per session for double chin treatment
Moridpour AH, Kavyani Z, Khosravi S, et al
While GLP-1 receptor agonists are generally well-tolerated, certain symptoms warrant prompt medical evaluation
As a glucagon-like peptide-1 (GLP-1) receptor agonist, Semaglutide mimics the incretin hormones in the body, enhancing insulin secretion in a glucose-dependent manner, suppressing inappropriate glucagon secretion, and slowing gastric emptying to promote satiety and reduce appetite